Viridian Therapeutics, Inc.\DE (VRDN) — Institutional Holders, Q2 2026 (page 3)

215 institutional investment managers reported a VRDN position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $2.5B. Every filer is listed below, ranked by position value, 100 per page; this page shows ranks 201 to 215. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.

VRDN 13F holders ranked 201–215 of 215

Institutional investors reporting a position in Viridian Therapeutics, Inc.\DE on SEC Form 13F-HR for Q2 2026, ranked by reported value.
InstitutionValueQoQ
SJS Investment Consulting#201 · 110 sh$2.0KNew
Ameritas Advisory Services#202 · 80 sh$1.5KNew
ZIONS BANCORPORATION, NATIONAL ASSOCIATION#203 · 74 sh$1.4K-17.8%
Parallel Advisors#204 · 65 sh$1.2K-21.7%
Covestor Ltd#205 · 29 sh$1.0K+480.0%
LRI Investments#206 · 46 sh$845.00New
Owl Creek Wealth Partners#207 · 45 sh$827.000.0%
Essential Partners#208 · 31 sh$569.00New
Torren Management#209 · 21 sh$386.000.0%
Wealth Enhancement Services#210 · 20 sh$367.00New
SIGNATUREFD#211 · 19 sh$349.00-72.1%
IFP Advisors#212 · 10 sh$184.000.0%
Pinnacle Wealth Planning Services#213 · 8 sh$147.00New
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM#214 · 91,402 sh—+12.8%
Elequin Securities#215 · 71 sh—New

Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.